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Abstract  
Introduction 
Treatment of locally advanced vulva cancer (LAVC) remains challenging. Due to the 
lack of randomised trials many questions regarding the indications for different 
treatment options and their efficacy remain unanswered.  
Methods 
In this retrospective study we provide the largest published series of LAVC patients 
treated with anovulvectomy, reporting oncological outcomes and morbidity. 
Additionally, a systematic literature review was performed for all treatment options 
1946 - 2015.  
Results 
In our case series, 57/70 (81%) patients were treated in the primary setting with 
anovulvectomy and 13 patients underwent anovulvectomy for recurrent disease. The 
median overall survival (OS) was 69 months (1-336) with disease specific survival of 
159 months (1-336). Following anovulvectomy for primary disease, time to 
progression and OS were significantly higher in node negative disease (10 vs. 96 
months; 19 vs. 121 months, p<0.0001). Post-surgical complications were observed 
in 36 (51.4%), the majority of which were Grade I/II infections. There was one peri-
operative death. 
Review of the literature showed that chemotherapy, radiotherapy or combination 
treatments are alternatives to surgery. Evidence relating to all of these consisted 
mostly of small retrospective series, which varied considerably in terms of patient 
characteristics and treatment schedules. Significant patient and treatment 
heterogeneity prevented meta-analysis with significant biases in these studies. It was 
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unclear if survival or morbidity was better in any one group with a lack of data 
reporting complications, quality of life, and long term follow-up. However, results for 
chemoradiation are encouraging enough to warrant further investigation.  
Conclusions 
There remains inadequate evidence to identify an optimal treatment for LAVC. 
However, there is sufficient evidence to support a trial of anovulvectomy versus 
chemoradiation. Discussions and consensus would be needed to determine trial 
criteria including the primary outcome measure. Neoadjuvant chemotherapy or 
radiotherapy alone may be best reserved for the palliative setting or metastatic 
disease.  
Word Count: 299 
Key Words: Locally advanced vulval cancer (LAVC); anovulvectomy; colostomy; 
chemoradiation; exenteration  
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Introduction 
Surgery forms the cornerstone of management of vulval cancer.  Approximately one 
third of vulval cancer patients present with locally advanced vulval cancer (LAVC)[1], 
for which there is little consensus regarding its definition. We have defined LAVC as 
cancers which encroach upon or cross the borders with surrounding structures such 
as the urethra or anus. Interest in non-surgical alternative more conservative 
approaches for this subset of women stems from the recognised psychosexual 
sequelae and physical morbidity associated with radical surgical resection and in 
particular, the need for a stoma. There has been little progress made in the last 20 
years  in the development of guidance for treatment of LAVC and it should be 
acknowledged that the evidence to date for managing LAVC is entirely based on 
small phase II trials, uncontrolled studies or retrospective case series without 
matched controls. It is therefore difficult to group or compare patients owing to the 
significant heterogeneity in both the patient populations as well as variation in the 
treatment approach and the complicating factor that many patients treated by 
primary chemoradiation would have been considered unsuitable for surgery by 
numerous institutions. Modern medicine dictates the use of evidence-based 
medicine and in this review we collate the available evidence for surgical 
management as well as the alternative approaches of chemotherapy, radiotherapy 
and combination modalities.  
In addition, we provide our institute’s experience of the surgical management of 
locally advanced peri-anal tumours treated with anovulvectomy, which comprises the 
largest series from a single tertiary centre over 36 years and report the oncological 
outcomes and morbidity. Finally, we discuss the need and feasibility of a clinical trial 
to address many of the unanswered questions.  
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Methods 
Case Series 
A retrospective review of women, 1978 – 2014, with LAVC treated by anovulvectomy 
at the Northern Gynaecological oncology Centre, UK was conducted. Data from 
operative records, pathology reports, medical records, the MDT database and death 
certificates were accessed in conjunction with morbidity data from the prospectively 
collected departmental database.  
The staging workup for patients with LAVC is not standardised. In our institute all 
patients underwent examination under anaesthesia and preoperative imaging (MRI 
/CT, from 1990) to define extent of local tumour, lymph node status and presence of 
distant metastatic disease. PET has been introduced in more recent years to 
evaluate metastatic disease. In primary diagnosed cases, bilateral groin node 
dissection (BGND) was also performed. The operative procedure is described in 
Supplementary Box 1.[2]All vulval biopsies and excision specimens were reported as 
advised by the Royal College of Pathologists’ Standards and datasets for reporting 
cancers [3]. The new FIGO staging (2009) was retrospectively determined in all 
cases predating the revised guidelines [4]. Follow-up was to the last date seen in the 
outpatient clinics, or last contact by patient or GP.  
Primary oncological outcomes included time to progression and overall survival 
(OS). Univariate associations between these endpoints and other variables were 
examined using Chi2 or Fisher’s exact test, as appropriate. Secondary outcomes 
focused upon treatment-related morbidity.  Peri-operative and long-term side-effect 
frequencies were reported. For OS, patients who died at follow-up (any cause) were 
considered uncensored, whereas patients alive at last follow-up, or lost to follow-up 
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were censored. Univariate analyses for OS and PFS were generated by Kaplan–
Meier survival curves and log-rank (Mantel–Cox) tests for statistical significance. 
Systematic Literature Review 
The aim of this systematic review was to assess the evidence for the impact of 
surgery, radiotherapy, chemotherapy, and combination chemoradiation treatments 
on survival in patients with histologically proven LAVC. The secondary objective was 
to assess associated morbidity with each of these treatment modalities including 
preservation of anus.    
A systematic literature search was conducted in December 2015 using the PRISMA 
guidance [5]. MEDLINE (1946 to 2015), EMBASE (1980 to 2015), Web of Science 
and relevant Cochrane registers were searched. Controlled vocabularies and key 
words that were related to “vulva* cancer*/carcinoma*/malignan*/neoplasm*”, 
“anovulvectomy”, “exenteration”, “chemotherap*” and “radiotherap*/radiation” were 
used in a search strategy. In addition, hand searching the reference lists of previous 
related review articles was performed. Title/abstract screening, full-text review, data 
extraction, and quality assessment were performed. Data regarding the patient 
group, treatment modality regimen, secondary treatments and survival was extracted 
along with reported morbidity, where available. Articles without an available English 
translation and case studies of single patients were excluded.  Both prospective and 
retrospective studies were included.  
Results 
Case Series 
In the 36 year study period 70 patients underwent anovulvectomy for primary or 
recurrent LAVC. The median age of diagnosis was 69 years (30 - 91) with 68/70 
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(97.1%) squamous cell carcinomas, one adenocarcinoma and one adenoid cystic 
carcinoma. 57/70 (81.4%) patients underwent anovulvectomy as primary treatment 
for histologically-proven vulval cancer, 56 of which underwent BGND. One patient 
with a Bartholin’s gland SCC did not undergo lymphadenectomy.  
Median length of follow-up for the entire cohort (primary and recurrent disease) was 
39 months (0 - 336 months). 19/70 (27.1%) patients received adjuvant treatment 
post-operatively; 17 of whom received groin radiotherapy for groin node metastases 
(+/- vulva radiotherapy for close resection margin(s)); one had chemotherapy, and 
one had combination chemo-radiation for extra-pelvic node metastases.  
Anovulvectomy for primary treatment of LAVC 
For the primary surgery group (n=57), 12 (21.1%) had Stage II, 37 (64.9%) had 
Stage III and 8 (14.0%) had Stage IV, Table 1. The median tumour size was 70 mm, 
(20 - 200 mm) in the single largest diameter. All tumours reached near the anal 
margin and for one patient there was suspicion of a recto-vaginal fistula. Surgical 
margin, following fixation, ranged from 0 (disease at margin) to 17 mm, with a 
median margin of 5 mm.  Complete primary closure of the vulval wound was 
achieved in 21 (36.8%) cases. The remaining patients had the vulval wound left 
partially or completely open to heal by secondary intention. No cases underwent 
reconstructive or plastic surgery. There was no delay in receiving adjuvant therapy in 
the 19 patients in whom this was indicated, due to vulval wound complications.    
Of the 24 (42.1%) patients with margins less than 8 mm after fixation, 21 had 
tumours greater than 50 mm in their largest diameter. Two patients underwent 
further surgical excision and 10 received further treatment with radiotherapy. 25 
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(43.9%) patients had one or more positive groin nodes, of which 12 (21.1%) were 
bilateral.  
Survival for all cases was not significantly associated with age, tumour size or 
resection margin. However, survival was positively associated with lymph node 
status and stage. As expected, prognosis was significantly worse in node positive 
disease in comparison to node negative disease, Figure 1, Table 1. Median time to 
progression in the node positive group was 10 months, in comparison to 96 months 
in the node negative group, log-rank, p<0.0001). Median OS was 19 months in node 
positive disease in comparison to 121 months in node negative disease, log-rank, 
p=0.0010, Figure 1.  
Anovulvectomy for locally recurrent disease 
The 13 patients who underwent anovulvectomy as treatment for recurrent vulval 
cancer included 4 (30.8%) patients with Stage 1 disease, 7 (53.8%) with Stage 2 and 
2 (15.4%) with Stage 3 disease. All patients were managed primarily with surgical 
excision, four of which had undergone previous multiple surgical procedures. Twelve 
patients had previously undergone lymphadenectomy (1/12 node positive) and two 
patients had also received groin radiotherapy. The median disease free interval 
following primary treatment was 72 months (range 7 - 336 months). Following 
treatment of recurrent LAVC with anovulvectomy only one patient had complete 
primary closure of the vulval wound, with the remaining 12 patients having partially 
or completely open vulval wounds to heal by secondary intention. Following 
anovulvectomy, the median time to further disease recurrence was 14 months (0-76) 
with additional median survival following anovulvectomy of 25 months (0-156).  
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Morbidity 
Median duration of hospitalisation after surgery was 16 days (range 1 – 90). The 
length of stay reduced with time reflecting developing clinical practice with a median 
inpatient stay of 29 days in 1990s compared with only 14 days in 2000s. 41/70 
(58.6%) patients experienced one or more post-operative complications. 81.3% of 
which were Clavien Dindo Grade I/II and the majority of which were superficial 
wound breakdown or minor infective complications, which resolved following 
antibiotic therapy. There were 11 cases of post-operative lymphoedema and six 
stoma complications, with one patient requiring refashioning of the colostomy before 
discharge. There was one peri-operative death, caused by a myocardial infarction 
(MI) on post-operative day 4. A further five patients experienced treatment related 
complications which included two MIs, one cerebrovascular accident and three 
pulmonary emboli. During follow-up, five patients reported vaginal prolapse and 
elected to undergo prolapse surgery and there were three patients who reported 
symptoms resulting from the rectal stump. Of those that had died, 27 (67.5%) died of 
disease, and 13 died of other causes, the majority of which were secondary to 
advanced cardiological or respiratory co-morbid conditions. 
The rate of complications observed in this series is low in comparison to similar case 
series treated with pelvic exenteration. In one exenteration case series, in which the 
indication for exenteration was primary LAVC in the majority, the authors report a 
mortality rate of 7%, of which intra-operative mortality accounted for 3.5% [6]. 
Additionally, with exenteration major complications occurred in 42.9%, with early 
complications including massive bleeding from the sacral plexus, adult respiratory 
distress syndrome, acute renal failure, ureteric imjury, re-operation and pulmonary 
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embolus. This is further supported by several other reports in gynaecological series 
[7-9].  
Literature Review 
191 articles were identified from the initial search for further evaluation. A majority 
were review articles published in oncology journals or case series with 43 studies 
included in the review. There were no randomised controlled trials (RCTs) directly 
comparing the different treatment modalities and no case controls in the studies 
included. The heterogeneity of articles and differences in definitions and outcomes 
made this unsuitable for a meta-analysis. 
Radical Surgery (n=12 studies) 
It is largely accepted that if it is possible to resect the primary tumour with clear 
surgical margins without damaging the urethra or anal sphincter leading to urinary or 
faecal incontinence, primary surgical excision is typically the preferred treatment.  
When the disease involves the anus, rectum, rectovaginal septum, proximal urethra, 
or bladder, in order to obtain adequate surgical margin, some form of pelvic 
exenteration may be required necessitating permanent colostomy and/or urinary 
diversion and therefore may only be appropriate in carefully selected cases. Since 
the 1970s pelvic exenteration has been repeatedly discussed and evaluated in small 
studies [10-12], with variable oncological outcomes and varying degrees of 
associated morbidity [13, 14], Table 2.  Historically, 5-year survival after pelvic 
exenteration for vulval cancer has been reported around 50%, but, survival is related 
to lymph node status, with a poor prognosis when groin lymph nodes are found to be 
positive [15-18].  
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As alternatives to exenteration there have been several published series, including a 
series by Hoffman et al who described the use of radical local excision (complete 
anal resection without colostomy, anal resection with partial resection of the 
sphincter, and partial removal of the anal skin) [19]. This however resulted in faecal 
incontinence in 100% of the first group, 50% of the second and 11% of the third. 
Adams et al reported on the use of proctectomy combined with vulvectomy and 
BGND in a small series of five patients [20]. This was a single-step procedure, with 
stapling of the rectum and creation of a transverse colostomy and mucus fistula. It 
was not possible to comment on long-term survival as only 3/5 patients were alive 
and free of disease after a relatively short period of follow-up. A small series from our 
own institution (n=23) [21], which has been included in the case series in this review, 
reports the use of anovulvectomy for LAVC.  This approach offers a treatment with 
good survival outcomes and with relatively low morbidity.  
When considering all radical surgery collectively, surgery has a reported post-
operative mortality rate ranging from 0% to 20%, with a mean of about 4% [1].  
Psychological morbidity can also be considerable but there is a lack of robust 
published evidence to quantitate or assess it directly. Sexual impact of vulvectomy 
has not been assessed however, a systematic review and meta-analysis on quality 
of life after surgery for rectal cancer, found no significant differences in quality of life 
in rectal cancer patients with a permanent stoma when compared to non-stoma 
patients [22, 23]. No similar data is available for LAVC.  
Overall when considering all surgical approaches, including exenteration as well as 
our series of anovulvectomy, surgical excision has been shown to result in good 
survival outcomes. The cumulative disease-free survival is reported at 46% overall 
and as with early stage vulval cancer, prognosis correlates well with lymph node 
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status [1]. This is frequently at the cost of performing a stoma but data reporting the 
physical and psychological consequences of this is lacking.  
Reconstructive surgery 
A full discussion of reconstructive surgery following radical excision of LAVC is out 
with the scope of this review but it should be acknowledged that reconstructive 
options includes skin grafting as well as the use of flaps. Skin grafting is challenging 
in this area as it is difficult to avoid shearing forces and infection with delayed healing 
or graft loss being common [24]. Contractures can also be problematic, interfering 
with functions such as urination and intercourse [25]. Additionally, if patients have 
previously received local radiotherapy, reconstructive surgery is more challenging 
and may be associated with higher rates of morbidity. There is a lack of evidence 
comparing primary/secondary closure with reconstructive surgery.  
Neoadjuvant radiotherapy (n=5 studies) 
Over the last 2 decades, the use of primary radiotherapy (RT) for patients with stage 
III-IVA vulval cancer increased from 18% in 1988 to 30% by 2008 [26]. Boronow et al 
first reported neoadjuvant RT followed by surgical resection as an alternative to 
pelvic exenteration in 1982 [27]. In this series of 48 patients, 77% received 
preoperative RT followed by radical vulvectomy. No residual disease was identified 
in 42.5% of surgical specimens and exenteration was performed in four cases. The 
5-year survival rates were 75.6% for the primary cases, 62.6% for the recurrent 
cases, and an overall 72% for all 48 cases treated. Hacker et al published similar 
findings in eight patients treated with preoperative RT with satisfactory shrinkage of 
tumour in 87.5%, [28]. However, in the series of 16 patients, 11 of which had peri-
anal disease, treatment by RT to the vulva, inguinal and pelvic nodes, followed by 
radical vulvectomy and lymphadenectomy, failed in 6 (37.5%) patients, necessitating 
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colostomy formation [29]. Despite macroscopic excision margins of 2 cm, 5/14 
showed microscopic disease within 1 cm of the margin, three of which later 
developed local recurrence and a further 25% of patients developed central 
recurrence disease.  
Although the data are limited, it appears that preoperative RT alone (45-54 Gy EBRT 
± 24 Gy brachytherapy) may downsize of the tumour in 70% - 85% of patients, 
reducing the need for exenterative surgery. This is unavoidable in some, see Table 
3. Additionally, this approach is also associated with significant morbidity. Following 
neoadjuvant RT, surgery and subsequent healing may be compromised by poor 
local blood supply and lymphatic drainage. Radiotherapy also carries risks of skin 
desquamation, wound cellulitis with subsequent prolonged hospitalisation, bowel and 
bladder toxicity and contractures. Furthermore, a temporary bowel diversion may be 
required for patients to be able to tolerate and complete a course of radiation 
therapy. Even with combined therapy, 50-70% of advanced stages may recur [30].   
Further data upon short and long-term morbidity as well as survival are needed. 
Based upon a reasonably good response rate from these series, further investigation 
of this modality appears warranted especially in groin node positive cases where 
radiotherapy to the groins may be given simultaneously and where the long term 
prospects appear to be poor with all of the treatment options.  
Neoadjuvant chemotherapy (n=5 studies) 
Different chemotherapy regimens have been used in LAVC with varying degrees of 
success, Table 4. All of the studies suggest that vulval cancer responds to 
chemotherapy to a variable extent and there is evidence that some cancers can be 
rendered more operable. In an EORTC Phase II study of neoadjuvant treatment with 
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triple combination therapy (Bleomycin, methotrexate and lomustine) complete 
response was seen in only 8%, and partial response in 48% [31]. The 1 year survival 
was only 32% and this regimen was associated with major haematological side 
effects and mild signs of bleomycin-related pulmonary toxicity.  In another series of 
21 stage IV patients, Benedetti-Panici, et al reported partial response in the size of 
the primary tumour in two patients and partial/complete response in the inguinal 
node disease in 14 patients [32].   All patients required radical vulvectomy but the 
therapeutic results were poor with a 3-year survival of 24%. Sixty-eight percent of the 
operated patients recurred 3-17 months from the end of treatment and 50% of them 
had a distant relapse.  
Giesler et al showed no clinical response with cisplatin alone but partial clinical 
response following combination treatment with cisplatin and 5-FU [33]. All patients 
underwent radical vulvectomy following NACT and the anal sphincter and urethra 
were conserved in all patients receiving combination chemotherapy.  
Recurrence remains a problem even after successful surgical removal of residual 
disease with 20/27 patients who completed treatment with NACT followed by surgery 
developing local/nodal recurrences in one study [34]. Toxicity of chemotherapy may 
also be problematic with severe haematological toxicity and gastro-intestinal toxicity 
all being well documented.   
Overall, the role of neoadjuvant chemotherapy appears limited but may serve a role 
in those cases unsuitable for surgery or radiotherapy treatments, in those with 
distant disease or in the palliative setting in select cases.  
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Concurrent chemoradiation with or without subsequent surgery 
(n=19 studies) 
The addition of chemotherapy concurrent with RT for LAVC was influenced by 
advances in the treatment of anal squamous cell carcinomas, which showed 
improved local control and colostomy-free survival with the addition of fluorouracil (5-
FU) and mitomycin C [35, 36]. Several small studies have assessed the feasibility 
and activity of concomitant chemoradiation in a neoadjuvant setting followed by 
tailored surgery for LAVC with a variety of regimens and agents used, Table 5.  
The combination of bleomycin and RT was disappointing [37, 38]. The use of RT 
with single-agent 5-FU or 5-FU with mitomycin C [39-46] or 5-FU with cisplatin [47-
55] has demonstrated variable but promising response rates. The GOG undertook a 
phase II trial (GOG 101) to determine feasibility of using preoperative 
chemoradiation (5-FU with cisplatin) [56]. 71 patients underwent treatment with 
chemoradiation followed by surgical excision and BGND, which resulted in an overall 
response rate of 46.5%. Only 2.8% had residual unresectable disease, and among 
the 50 patients initially requiring exenterative surgery, only one patient necessitated 
exenteration and two required colostomy. At a median follow-up of 50 months, 
32.9% developed recurrence and 54.9% were alive without recurrent disease. The 
authors concluded that toxicity was acceptable, with acute cutaneous reactions to 
chemoradiation and surgical wound complications being the most common adverse 
effects.  
The subsequent GOG 205 Phase II study using a combination of weekly cisplatin 
with RT resulted in complete clinical response in 37/40 (92.5%) patients. Of the 34 
patients who underwent biopsy, 29 had a complete pathologic response. The 
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authors concluded that this combination of therapy successfully yielded high, 
complete clinical and pathologic response rates with acceptable toxicity [57].  
Despite these findings, a Cochrane review of five series concluded that the 
combination of chemoradiation and radical surgery is associated with significantly 
more morbidity than either treatment given on its own [58]. The combination of 5-FU 
and mitomycin C is associated with high rates of toxicity and subsequently this 
regimen has not been used in the newer chemoradiation studies in other cancer 
types. Skin and subcutaneous atrophy is common and wound breakdown occurs in 
20–31% of the patients [25]. Severe complications can include bowel perforation, 
bowel obstruction, avascular hip necrosis, and toxic deaths. Surgical interventions 
after chemoradiation have high complication rates and the impact of tumour bed 
resection in cases of complete remission is unclear [24]. Additionally, acute toxicities 
may necessitate radiotherapy interruptions and dose modifications, compromising its 
treatment effect [59].  
Collectively available studies have demonstrated that pre-operative combination 
chemoradiation is feasible and may reduce the need for more radical surgery. 
However, this is at a cost of a lower local control rate compared with primary 
surgery.   
Concurrent chemoradiation versus surgery (n=3 studies) 
Scarce prospective data are available on the treatment of LAVC in the curative 
setting with primary chemoradiation without planned surgery. A systematic review 
specifically comparing chemoradiation in LAVC to other treatment modalities by 
Shylasree et al [60] included two retrospective series [46, 61] of primary 
chemoradiation versus primary surgery and one RCT [62] of neoadjuvant 
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chemoraditation versus primary surgery in patients with operable disease. None of 
the studies showed a survival benefit for either treatment option and no differences 
in morbidity could be demonstrated. However, study populations are small and the 
RCT discussed has not been published as a full paper version. In addition, reporting 
of morbidity was incomplete and none of these studies include data on quality of life 
[60]. 
Targeted Therapies 
There are no published trials of targeted biological agents in LAVC. There is 
however one ongoing Phase II study of Pazopanib (a tyrosine kinase inhibitor and 
vascular endothelial growth factor inhibitor) registered with the Clinical Trials 
Register, which includes advanced vulval cancer as well as other gynaecological 
malignancies[63] .  
Recurrent disease 
The majority of case series and studies to date have focused upon the treatment of 
LAVC in the primary setting. Although some cases of recurrent disease have been 
included in some reports overall there is little published evidence addressing the 
specific needs of this group of patients.  
Discussion 
It would appear from the literature review, which includes our own institute’s 
experience of anovulvectomy, that there remains a strong case for surgical 
management of LAVC, especially in node negative cases, with good reported 
disease specific survival. Our study of anovulvectomy presents the outcomes from a 
single institution across nearly 5 decades, wherein management policies have 
remained relatively unchanged. We conclude that radical anovulvectomy is at least 
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an equivalent treatment in terms of survival with disease specific survival of 35 
months (1-336). Surgery however carries with it the physical and psychological 
morbidity including procedure related morbidity, physical disfigurement, 
psychosexual sequelae and a largely unknown impact on overall quality of life. 
Studies from colorectal patients with stomas suggest that the impact is less than 
many speculate but definitive studies of this are lacking in our cohort. The morbidity 
reported in this case series is modest with complications occurring in 41 (58.6%) 
patients and we believe that the risk of surgical complications can be reduced by 
good surgical technique by surgeons experienced in management of advanced 
vulval cancer alongside high quality peri-operative care and careful patient selection. 
Given the location of many LAVCs, many patients present with pain and physical 
limitations. Therefore, surgery may also be indicated for rapid palliation of disabling 
symptoms. 
The alternative approach of chemoradiation remains experimental but the data for 
this multimodal treatment, especially in the neoadjuvant setting has reported good 
survival, comparable to that of surgery, and has also been shown to result in a 
reduction in the rate of stoma formation. Stomas however may still be necessary in a 
proportion of patients. The extent of treatment related side effects are not well 
described, especially in those who still require surgical excision, but there is a 
suggestion that the combination of chemo, radiotherapy and surgery, albeit it a more 
conservative excision, may still result in significant morbidity and it is unclear if these 
cumulative treatment-related side effects result in more of an impact upon overall 
quality of life in comparison to stoma formation. Conversely, a proportion of patients 
who undergo upfront anovulvectomy with narrow resection margins or positive lymph 
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nodes will require radiotherapy and it is unclear if this treatment order results in less 
morbidity and better outcomes in comparison to neoadjuvant chemoradiation.  
The literature for the use of chemotherapy in the treatment of LAVC is relatively 
clear, confirming our concerns. In comparison to radical surgery, chemotherapy has 
been shown to be associated with poor survival and significant treatment related 
toxicity. It is our view that chemotherapy is therefore best reserved for use in the 
palliative setting, in patients with distant disease, or where the presence of significant 
co-morbidities precludes chemoradiation or surgical treatments. 
The ideal alternative treatment would improve both survival and quality of life, 
without increasing complications and morbidity but it is clear that there is no 
universal recommendation that can be made for all patients. Accepting that many 
patients affected by LAVC are largely elderly, often with significant morbidity, many 
may not be suitable for all treatment modalities and therefore we still need to 
maintain a degree of personalisation of care. Survival outcomes should be 
considered alongside the associated side-effect profiles of each modality enabling 
appropriate treatments to be selected for each individual. However, for those 
patients whose treatment options are not restricted there remain many unanswered 
questions.  
Despite a number of publications from recognised institutions, uncertainty regarding 
optimal treatment remains and it is unlikely that additional case series will add 
sufficient evidence to dictate a change in current practice. LAVC however represents 
a relatively small proportion of any individual institutions’ caseload and it is evident 
that different centres have their own approach. These variations in treatment 
practices represents a state of clinical equipoise presenting the opportunity to 
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explore this dilemma and answer the question of optimal treatment in a clinical trial. 
To our knowledge, there are currently no plans for any randomised trials. Published 
series to date have supplied the baseline data necessary for such a study providing 
an understanding of the important clinical endpoints. It is not disputed that any RCT 
in this cohort of patients will have its own limitations owing to the rarity of LAVC, the 
complicating factors of variable tumour size, patient comorbidities and difficulties in 
randomisation. However, accepting that these are limitations that can be overcome 
through consensus we present the basis of a RCT where these factors would need 
to be debated. 
Topics for debate include: 1) designing the control and investigational arms of an 
RCT. Based upon the observed good survival seen in the review of radical surgical 
resection, and the achievement of local disease control and symptoms, we propose 
radical surgery to be the standard treatment arm. In light of the promising survival 
outcomes achieved with chemoradiation alongside a possible reduction in the need 
for radical surgery including stoma formation, we recommend chemoradiation with or 
without additional tailored surgery for the investigational arm.  
2) Sample size and feasibility. One of the greatest anxieties about an RCT in this 
setting is the ability to recruit adequate numbers of patients with sufficient follow-up.  
A primary outcome of a modest survival difference of 5-10% between the two arms, 
powered to 90% with significance set at p=0.05, two tailed (as uncertainty as to 
which treatment would provide an improved survival) would require a sample size of 
approximately 500 patients, which is not unrealistic in an international setting.  
Alternatively, an RCT powered to show equivalence in terms of survival with the 
primary outcome measures of quality of life and/or morbidity may provide a more 
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robust assessment of these very relevant aspects but would necessitate a larger 
sample size.  
3) Outcome measures. For many clinicians and patients endpoints relating to quality 
of life may be considered the most important, in particular the impact of stoma 
formation. The challenges of selecting the methodologies for assessment of such 
endpoints may however be complex and although there are several validated 
questionnaires available for assessment of psychosexual health, anatomical 
disfigurement, incontinence and overall quality of life, it is not clear if they are all 
suitable for this study and consensus for their use would be required. Incorporation 
of evaluation of QALYs and cost-effectiveness of each treatment modality is also 
desirable but may be challenging in an international setting.  
4) Inclusion, exclusion criteria and stratification. Despite the variable approaches to 
treatment all published studies show a clear stratification of cases in terms of 
survival according to lymph node status. Without prior stratification of patients by 
node status, sub group analysis for both survival and qualitative measures would be 
required. This could be compensated for in the initial sample size calculation or 
patients with node positive disease could be excluded from the randomisation. 
Owing to the poor survival universally seen in node positive disease, these patients 
should be considered for a more conservative approach and analysed separately 
from the rest of the cohort 
5) Pre-treatment investigations. The question of how to clarify nodal status prior to 
selection of treatment modality therefore needs to be addressed and without 
consensus on how lymph node status should be determined radiological assessment 
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(CT/MRI/PETCT) or surgical sampling should be considered for inclusion in the 
study protocol.  
6) Treatment regimens. Within the surgical treatment arm, the heterogeneous nature 
of the anticipated procedures performed may complicate analysis with the need for 
inclusion of surgical complexity scores, measures of surgical quality assurance, 
patient reported evaluation of disfigurement, impact upon quality of life including 
psychosexual issues necessary to enable holistic evaluation of the selected 
treatment. The optimum chemoradiation treatment schedule to be used also requires 
clarity with a variety of regimens described in the literature. In addition, evaluation of 
response to chemoradiation will also require standardisation with a need for clinical 
and histological confirmation of response, particularly if a secondary surgical 
excision is deemed unnecessary.  
Accepting that there are numerous and complex issues to take into consideration, it 
is also clear that we are in a state of clinical equipoise with evidence that can be best 
described as conflicting, biased and inadequate. Due to the rarity of the condition 
and the lack of patient support groups in vulva cancer promoting and demanding 
better research in this cancer site it is not surprising that it features low in the priority 
list of most national and international research groups rendering it into a “Cinderella” 
status. So we should ask ourselves, is locally advanced vulvar cancer really in the 
“too difficult to do” box?  
Conclusion 
Treatment of LAVC with radical surgery, including anovulvectomy continues to be a 
standard of care which results in good survival outcomes and acceptable morbidity. 
Neoadjuvant chemotherapy or radiotherapy alone may be best reserved for the 
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palliative setting or metastatic disease. There is also evidence to support the 
alternative approach of chemoradiation as the investigational arm of a definitive 
RCT. Direct comparisons with the standard approach of radical surgery are required 
to address the uncertainty of survival outcomes, morbidity and quality of life 
measures between the two treatment approaches.  
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Table Legends 
Box 1: Operative Anovulvectomy Procedure 
Table 1: Table of patient demographics, histopathological diagnoses and survival 
Table 2: Radical surgery 
Table 3: Neoadjuvant radiotherapy 
RT = radiotherapy; BGND = bilateral groin node dissection; EBRT = external beam 
radiotherapy; Gy = Gray 
Table 4: Neoadjuvant chemotherapy 
CDDP = cisplatin; Bleo = bleomycin; MTX = methotrexate; EBRT = external beam 
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Tables and Figures  
Box 1 Operative Anovulvectomy Procedure 
Examination under anaesthesia is performed to assess the extension of the tumour 
and groin node involvement.  
A catheter is inserted and the patient is in a supine position. Pre-1990 a midline 
laparotomy was performed to assess the abdominal and pelvic cavity for metastasis 
and pelvic and para-aortic lymph node involvement. If palpable lymph nodes were 
found, a pelvic lymph node dissection was performed. This was later omitted in 
patients with no radiological evidence of lymphadenopathy. A permanent sigmoid 
end colostomy was formed, with stapling or oversewing of the distal segment of 
bowel. The midline laparotomy incision was later modified to a parastomal incision.  
In primary diagnosed cases, bilateral groin node dissection is performed with 
separate linear groin incisions [2]. Closed suction drains are placed in the groin 
wounds and are maintained for 5 days post-op. 
The patient is moved to the lithotomy position and radical excision of the vulval 
tumour is performed with the limits of the excision marked at 15-20 mm from the 
tumour edge, aiming for margins >10 mm after fixation. The exact limits will vary 
depending upon the location and extent of the lesion. Up to 2 cm of the distal urethra 
con be excised without interfering with continence. The anterior limit of the resection 
is grasped with Littlewood forceps and the incision deepened to the deep fascia. The 
entire vulva is then removed by sharp dissection in a posterior direction. The rectum 
is isolated by dissecting it from it’s surrounding tissue and from the pubococcygeus 
attachment. Next, the rectum is separated from the vaginal attachment.  With traction 
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applied to the surgical specimen, the rectum is cross-clamped, ensuring adequate 
margins. The rectal stump edges are oversewn for haemostasis and the stump is left 
open to allow drainage. The vulval defect produced is either closed primarily or left 
open and allowed to heal by secondary intention and a urethral catheter inserted. 
Interrupted deep mattress sutures reduce dead space and appose skin edges, 
where possible, without undue tension. The area is sutured down to the point a short 
distance above the urethral orifice to avoid a hood over the urethral opening. 
Thereafter the remainder of the vulva can be covered by opposing the lateral cut 
edge with the vaginal mucosa. At the end of the procedure it is usual to insert a 
bladder catheter which is maintained until vulval oedema has resolved.    
Post-operative care focuses upon prevention of wound complications with 
meticulous wound care, prevention of pain, constipation, and venous 
thromboembolism and early mobilisation. Sutures can typically be removed after 7 
days.   
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Table 1: Table of patient demographics, histopathological 
diagnoses and survival 
 Median (range) / n (%) 
Patient Age 69 (30 - 91) 
Presentation 
Primary 
Recurrent disease 
 
57 (81.4) 
13 (18.6) 
Stage 
Recurrent disease 
Stage 2 
Stage 3 
Stage 4 
 
13 (18.6) 
12 (17.1) 
37 (52.9) 
8 (11.4) 
Histology 
Squamous Cell Carcinoma 
Adenocarcinoma 
Other 
 
 
67 (95.7) 
1 (1.4) 
1 SCC Barts (1.4) 
1 Adenoid Cystic Carcinoma (1.4) 
Differentiation 
Well  
Moderate 
Poor 
 
14 (20.0) 
26 (37.1) 
30 (42.9) 
Time to recurrence (months) 
Overall 
Recurrent disease* 
Stage 2 
Stage 3 
Stage 4 
 
12.0 (0 - 122) 
14.2 (0 - 76) 
41.0 (6 - 96) 
14.0 (2 - 122) 
5.0 (1 – 38) 
Overall Survival (months) 
Overall 
Recurrent disease** 
Stage 2 
Stage 3 
Stage 4 
 
20.0 (1 - 336) 
24.0 (0 – 156) 
40.7 (12 - 121) 
18.0 (3 - 122) 
8.2 (1.5 – 77) 
% 1 yr Survival 
Overall 
Recurrent disease** 
Stage 2 
Stage 3 
Stage 4 
 
83.1 
91.7 
100.0 
84.4 
  37.5 
% 5 year Survival 
Overall 
Recurrent disease** 
Stage 2 
Stage 3 
Stage 4 
 
39.6 
25.0 
66.6 
50.0 
12.5 
Time to recurrence 
Node Positive 
Node Negative 
p<0.0001 
10.0 (1 -73) 
96.0 (6 - 122) 
Overall Survival 
Node Positive 
Node Negative 
p<0.0001 
19.0 (1 - 77) 
121.0 (8 - 122) 
*time to next recurrence following anovulvectomy; **additional survival following anovulvectomy 
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Table 2: Radical surgery 
Author Ref Year No. patients 
Primary/ 
recurrent 
disease 
Median 
age 
Positive 
nodes 
Treatment Survival 
Adams et al [20] 1979 5 5 primary 74  
(52-74) 
- Vulvectomy + proctectomy  - 
Philips et al [15] 1981 16 
(vulva/vaginal) 
10 primary 
6 recurrent 
53.5  
(33-75) 
3/9 Vulvectomy + exenteration 2 yr: 56% 
5 yr: 54% 
Cavanagh et al [16] 1982 13 13 primary 44  
(27-69) 
- Vulvectomy + anterior/posterior/ total 
exenteration 
5 yr: 50% 
Hoffman et al  [19] 1989 24 24 primary - - Partial/total anal resection +/- 
anovulvectomy 
- 
Grimshaw et al [21] 1991 23 23 Primary 64  
(35-85) 
7/22 Anovulvectomy 2 yr: 48% 
5 yr: 62% 
Remmenga et  al [64] 1991 5 5 primary  
(47-67) 
- Vulvectomy + partial anal and rectal 
resection  
- 
Hopkins et al [17] 1992 19 11 primary 
8 recurrent 
50  
(40-74) 
5/14 Anterior/posterior/ total exenteration 5 yr: 60% 
Barton et al [65] 
[65] 
[65] 
[65] 
1993 22 21 primary 
1 recurrent 
62  
(24-85) 
- Radical vulvectomy with plication of the 
external anal sphincter and puborectalis 
muscles 
- 
Miller et al [18] 1995 21 8 primary 
13 recurrent 
57  
(34-74) 
3/13 Anterior/posterior/ total exenteration - 
Maggioni et al [66] 
[66] 
[66] 
[66] 
2009 106 (9 vulva) Recurrent 54 
(30-79) 
- Anterior/posterior/total exenteration Median OS:16% 
(vulval) 
Forner et al  [67] 2012 27 9 primary 
18 recurrent 
66  
(35-81) 
10/27 Anterior/posterior/total exenteration 5 yr: 67% 
Kaur et al  [68] 2012 36  
(8 vulva/vagina) 
4 primary 
32 recurrent 
57  
(35-81) 
- Anterior/posterior/total exenteration 5 yr: 44%  
(57% vulval/vaginal) 
O’Donnell et al  2016 70 56 primary 
14 recurrent 
69  
(30-91) 
25/56 Anovulvectomy +/-BGND 69 (1-336) months 
5 yr: 39.6% (primary 
and recurrent cases) 
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Table 3: Neoadjuvant radiotherapy  
Author Ref Year 
No 
pts 
Primary/ 
recurrence 
FIGO 
Stage 
Primary 
treatment 
Pathologic 
response 
Secondary 
Treatment 
Survival 
 
Boronow et al  [27] 
[27] 
[27] 
1982 33 26 primary 
6 recurrent 
II: (1) 
III: 20 (5) 
IV: 3 
 
RT or 
brachytherapy +/- 
EBRT 
- Vulvectomy +/- 
BGND 
1 exenteration 
65% (primary); 
71% (recurrent) 
Hacker et al [28] 1984 8 Primary  EBRT  
(1 brachytherapy) 
No residual disease 
62.5%  
Vulvectomy 62.5%  
(FU 15mnths-
10yrs) 
Boronow et al [69] 
 
 
 
1987 48 37 primary III: 20 
IV: 4 
Other: 3 
RT or 
brachytherapy +/- 
EBRT 
No residual disease 
42.5% 
Radical vulvectomy,  
4 exenterations  
5 yr 75.6%  
Rotmensch et al [29[ 1990 16 Primary III: 13  
IV: 3 
400 rad vulva, 
4500 rad groins 
12/16 regressed 
with RT; 62.5% 
preservation 
viscera 
Radical vulvectomy 5 yr 45% 
Pohar et al [70] 1995 34 21 primary 
13 recurrent 
I: 2 
II: 8 
III/IV: 12 
60 Gy (53-88 Gy) 
brachytherapy 
- Nil 5 yr 29% 
RT = radiotherapy; BGND = bilateral groin node dissection; EBRT = external beam radiotherapy; Gy = Gray  
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Table 4: Neoadjuvant chemotherapy  
Author Ref Year 
Retrospective
/prospective 
Primary 
/recurrence 
Primary treatment 
No. of 
cycles 
Response 
Secondary 
Treatment 
Survival 
 
Benedetti-
Panici et al 
[32] 1993 Prospective 21 CDDP, bleo, MTX 2-3 90% operability 
(79% radical 
surgery), 33% 
pathologic 
downstaging 
79% radical 
surgery 
Progressive 
disease - EBRT 
24 % 3 yr survival 
Wagenaar et 
al  
[31] 2001 Phase II 
prospective 
12 primary, 
13 recurrent 
Bleo, MTX, lomustine 3 2 complete, 12 
partial (overall 
56%) 
 12% at 8 months. 
Median survival 
7.8 months. 1-yr 
survival 32% 
Geisler et al [33] 2006 Prospective 13 10 pts: CDDP, 5-FU; 
3 pts cis only 
2-4 (CDDP + 5-FU): 
9/10 partial, 1/10 
complete. No 
measurable 
response (CDDP 
alone).  
 
Radical 
vulvectomy 
+BGND 
CDDP + 5-FU: 
mean survival 79 
months; CDDP 
only: mean 9 
months 
Domingues 
et al  
[71] 2010 Retrospective 25 10 pts Bleo (A);  5 pts 
paclitaxel (B);  10 pts 
5-FU and CDDP (C) 
3 (A) 60%;  
(B) 40%;  
(C) 20% 
Radical 
vulvectomy 
2/5 radical 
vulvectomy 
(C) 2/10 radical 
vulvectomy 
70% 1 yr survival; 
30% 5 yr survival;  
60% / 20%;  
10% 1 yr survival.  
Aragona et 
al 
[73] 
[34] 
2012 Prospective 35 12 pts CDDP + 5-FU;  
6pts  CDDP + 
paclitaxel, 
6 pts CDDP + 
paclitaxel + 5-FU, 
6 pts vincristine + 
bleo + CDDP; 
5 pts bleo alone. 
3 71.4% partial 
5.7% stable  
 
22.9% did not 
complete therapy  
8 pts no 
surgery; 
14 pts radical 
vulvectomy; 13 
pts WLE; 
2 pts posterior 
exenteration, 
vulvectomy, 
BGND 
 
5 yr relapse free 
survival 89.5%. 
Mean relapse 
free OS 129.5 
months 
(excluding pts 
who did not 
complete 
therapy) 
Local recurrence 
in 20 patients 
CDDP = cisplatin; Bleo = bleomycin; MTX = methotrexate; EBRT = external beam radiotherapy; 5-FU = 5-fluorouracil. 
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Table 5: Concurrent chemoradiation with or without subsequent surgery  
Author Ref Year No pts Chemotherapy 
Total radiation Dose 
(Gy) 
Response 
Levin et al [40] 1986 6 5-FU, MitC 20-25 OR = 100% 
Thomas et al [41] 1989 24 5-FU +/- MitC 36-64 cCR = 58% 
Berek et al [49] 1991 12 CDDP + 5-FU 44-54 cCR = 67%, OR = 91.7% 
Russell et al [50] 1992 25 5-FU + CDDP (n=11) 34-72 cCR = 80%, pCR = 40% 
Koh et al [42] 
[42] 
1993 20 5-FU + CDDP (n=5) or +  MitC 
(n=1) 
40-54 cCR = 50%, cPR = 40% 
Sebag-Montefiore et al [39] 1994 32 5-FU, MitC 45-50 cCR = 47%, OR = 81% 
Eifel et al [51] 1995 12 5-FU + CDDP 40-50 OR = 91%, pCR = 33% 
Wahlen et al  [43] 1995 19 5-FU, MitC 45-50 cCR = 53%, cPR = 37% 
Landoni et al [45] 1996 58 5-FU, MitC 54 pCR = 31% 
Lupi et al  [44] 1996 31 5-FU, MitC 54 OR = 94% 
Cunningham et al [52] 1997 14 5-FU + CDDP 45-65 cCR = 64%, OR = 92% 
Leiserowitz et al [53] 1997 23 5-FU (n=6), or 5-FU + CDDP 
(n=17) 
54 (36-62.5) 7/9 no residual tumour at resection 
cCR = 14/23 
Moore et al [47] 1998 71 CDDP + 5-FU 47.6 cCR = 47% 
Han et al [48] 2000 54  
(20 CRT) 
5-FU + Mit C (n=14) or 5-FU + 
CDDP (n=6) 
45 + 6-17 to gross 
disease 
cCR = 54% 
Akl et al [54] 2000 12 5-FU + Mit C 30-36 ccR = 100% 
Mulayim et al [46] 2004 17 5-FU + Mit C or Mit C alone  32.4 (16.2-48) cCR = 85.7% (combined) 
cCR = 0% (MitC alone) 
Gerszten et al [55] 2005 18 CDDP + 5-FU 44.6 cCR = 72%, OR = 100% 
Gaffney et al (GOG 101 
Phase II) 
[56] 2009 71 5-FU + CDDP 47.5 OR = 46.5% 
Moore et al (GOG 205 
Phase II) 
[57] 2010 40 CDDP 57.6 cCR = 69% 
Adapted from [72]. 5-FU = Fluorouracil; MitC = Mitomycin; CDDP = Cisplatin 
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Figure  
Kaplan–Meier survival curves for time to progression and OS in patients with all stages of vulval cancer treated with primary ano-vulvectomy with lymph node (LN) 
positive versus LN negative disease. A: median time to progression was shorter in the LN positive group (10 months versus 96 months, log-rank, p<0.0001). B: 
median OS was 19 months in LN positive disease compared with 121 months in LN negative disease (log-rank, p<0.0001). C/D: a trend is seen in both time to 
progression and OS according to degree of LN involvement.   
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